Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health (NASDAQ:JAGX) has released results from a survey of 27 board-certified veterinary oncologists regarding Canalevia-CA1, their FDA conditionally approved treatment for chemotherapy-induced diarrhea (CID) in dogs.

Key findings show that 83.33% of surveyed oncologists emphasized the importance of Canalevia-CA1 being a non-antimicrobial treatment. Additionally, 62.5% expressed concerns about antimicrobial resistance with metronidazole, while 66.66% rated CID as having a moderate to large negative impact on dogs' cancer treatment adherence and quality of life.

Canalevia-CA1 is the first and only FDA-approved treatment for CID in dogs and is available through major veterinary distributors including Chewy. Jaguar Health is now seeking partners to expand the drug's indication for treating general, non-infectious diarrhea in dogs, targeting an estimated six million annual cases in the U.S.

Jaguar Health (NASDAQ:JAGX) has secured a Type C Meeting with the FDA in Q2 2025 to discuss the Phase 3 OnTarget trial results for Mytesi (crofelemer) in breast cancer patients. The trial focused on preventing diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy.

While the overall trial did not meet its primary endpoint across all tumor types, the breast cancer subgroup, comprising 183 of 287 participants, showed statistically significant responder analysis results. The study demonstrated that crofelemer prophylaxis resulted in a greater proportion of monthly responders for diarrhea improvement compared to placebo in breast cancer patients.

A late-breaker abstract with additional significant results has been submitted to the Multinational Association of Supportive Care in Cancer (MASCC) for their June 2025 Annual Meeting. The American Cancer Society projects 316,950 new breast cancer cases in US women in 2025.

Jaguar Health (NASDAQ:JAGX) has announced two upcoming investor events: a virtual presentation at the Emerging Growth Conference on March 27, 2025, and an investor webcast on March 31, 2025. The company plans to file its annual report on Form 10-K for the year ended December 31, 2024, on March 31, 2025.

CEO Lisa Conte highlighted that several key catalysts are expected in Q2 2025, primarily related to crofelemer development for rare diseases and cancer therapy-related diarrhea, which the company believes could enhance value.

The Emerging Growth Conference presentation is scheduled for March 27 from 3:40-3:50 PM ET, while the investor webcast will take place on March 31 at 8:30 AM ET to review Q4 2024 financials and provide corporate updates.

Jaguar Health (NASDAQ:JAGX) has secured a $3.448 million bridge financing through convertible promissory notes in a private placement priced at-the-market under Nasdaq rules. The company's CEO Lisa Conte, three board members, seven C-suite executives, and selected institutional and accredited investors participated in the financing.

The notes feature a 3-month maturity with a 6% annual interest rate and are immediately convertible into common stock. Additionally, investors will receive unregistered warrants exercisable immediately with a five-year expiration term. The offering is expected to close around March 27, 2025.

H.C. Wainwright & Co. serves as the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with the company agreeing to file a resale registration statement for the underlying shares.

Jaguar Health (NASDAQ:JAGX) has announced a 1-for-25 reverse stock split effective March 24, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol 'JAGX' with a new CUSIP number 47010C888.

The reverse split was approved by stockholders at a March 2025 Special Meeting, requiring majority approval from holders of Common Stock and Series J Perpetual Preferred Stock. According to CEO Lisa Conte, this strategic move aims to maintain Nasdaq listing compliance and achieve a more attractive share price and outstanding share count for institutional investors.

No fractional shares will be issued, with cash payments provided instead. Equiniti Trust Company, will serve as the exchange agent, managing the certificate exchange process for stockholders of record. Stockholders with shares in brokerage accounts or 'street name' require no action.

Jaguar Health (NASDAQ:JAGX) announced the approval of all proposals at its March 13, 2025 Special Meeting of Stockholders. The company highlighted several upcoming catalysts, including:

First results from proof-of-concept investigator-initiated trials of crofelemer for rare diseases short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID) are expected in Q2 2025. Additional trial results will follow throughout 2025.

The company also reported statistically significant results in the Phase 3 OnTarget trial's prespecified subgroup of breast cancer patients using crofelemer for cancer therapy-related diarrhea (CTD). A meeting with the FDA to discuss these results is scheduled for Q2 2025.

If successful with MVID patients, crofelemer may qualify for the EMA's PRIME program and FDA's Breakthrough Therapies program, potentially expediting development and review processes.

Jaguar Health (NASDAQ:JAGX) has implemented a duration stockholder rights plan following an acquisition interest. The plan aims to protect stockholder value by requiring potential acquirers to negotiate directly with the Board for purchases exceeding 20% of voting power.

The company anticipates key milestones in Q2 2025, including:

• First results from proof-of-concept trials of crofelemer for short bowel syndrome and microvillus inclusion disease
• FDA meeting regarding statistically significant Phase 3 OnTarget trial results for crofelemer in breast cancer patients

The Rights Plan includes a dividend of one preferred share purchase right for each common and non-voting share, exercisable at $4.50 if triggered. The plan has a one-year term and includes stockholder protections such as Board flexibility to consider full-value offers.

Jaguar Health (NASDAQ:JAGX) has received regulatory clearance from Italian and German health authorities for a Phase 2 study of crofelemer in adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF). The study, initiated on February 18, 2025, is part of five clinical efforts including three proof-of-concept trials and two Phase 2 studies for SBS-IF and microvillus inclusion disease (MVID).

The company expects the first proof-of-concept results potentially in H1 2025, with additional results throughout the year. Crofelemer, a plant-based anti-secretory prescription drug, has received Orphan-Drug Designation from both FDA and EMA for SBS-IF and MVID. These rare diseases affect approximately 10,000 to 20,000 people each in both the US and Europe, requiring intensive parenteral nutrition and significantly impacting patient quality of life.

Jaguar Health (NASDAQ:JAGX) and Napo Pharmaceuticals have extended their collaboration with Streeterville until January 2026 for developing NP-300, targeting cholera treatment and pursuing a Tropical Disease Priority Review Voucher (TDPRV). The FDA's TDPRV Program is currently the only active PRV program, potentially increasing voucher values which historically sold for up to $350 million.

NP-300 is a proprietary botanical extract distinct from crofelemer but with the same mechanism of action, sustainably derived from the Croton lechleri tree. The development targets cholera, which causes 1.3 to 4 million cases and 21,000 to 143,000 deaths annually worldwide. From January to July 2024, 307,433 cholera cases and 2,326 deaths were reported across 26 countries, leading WHO to classify it as a grade 3 emergency.